ICMR backed Covaxin could be ready by June 2021 ; Bharat Biotech


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ ICMR backed Covaxin could be ready by June 2021 ; Bharat Biotech
In the latest update on coronavirus vaccine, Covaxin, which is backed by the Indian Council for Medical Research and being developed by Bharat Biotech, is expected to be ready by June 2021.

Officials of Bharat Biotech have revealed that its coronavirus vaccine candidate Covaxin is expected to be ready by June 2021. Earlier on Thursday, the Drug Controller General of India (DGCI) allowed Bharat Biotech International Limited to conduct the Phase III trials of its Covid-19 vaccine candidate Covaxin.

Covaxin expected to be ready by June 2021
According to a report in the Indian Express, a top company official informed that Covaxin should be ready by June 2021-- unless the government advances its launch through emergency use authorisation.

"If we get all the approvals in place, I think during Q2 of 2021, we should get the efficacy readout from our phase-3 clinical trial — April, May, June, for example. That is for the full efficacy results," Sai Prasad, executive director, Bharat Biotech International Ltd, told The Indian Express.

Developed by Bharat Biotech along with the Indian Council of Medical Research and National Institute of Virology, Covaxin is India's first indigenous vaccine candidate against the Covid-19.

'Government may consider emergency use approval'
The official further said, "We are committed to doing all our phase-1, phase-2 and phase-3 clinical trials in its entirety, but I think the government may also be considering emergency use approval".

According to Indian Express, Prasad said that however, the firm is not pushing for such an approval.

“Our intent is to develop everything to its logical conclusion in terms of empirical evidence and data, and efficacy data and safety data. But there are discussions, I guess, within the government about that (emergency use approval),” he told Indian Express.

Story Source ; www.indiatoday.in 

Tags : #Covaxin #BharatBiotech #DCGI #LatestVaccineNewsOct24 #ICMR

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026